U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06976437) titled 'A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of Relapsed/ Refractory B-cell or Plasma Cell-derived Malignant Tumors' on May 09.
Brief Summary: A single arm, open-label pilot study is designed to determine the safety and efficacy of CD19 and BCMA targeted allogenic CAR-T cells (RN1101) in patients with relapsed/refractory B-cell or plasma cell-derived malignant tumors. 21 patients are planned to be enrolled in the dose-escalation trial (1x10^8 cells, 3x10^8 cells, 9x10^8 cells). The primary objective of the study is to evaluation of the safety and feasibility of RN1101 for the treatment of relapsed/refractory...